// App-Quantinova.ai

9014 : A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naive patients with advanced NSCLC.

Researchers

Presenter

  • Aaron Elliott Lisberg

Principal Investigators

  • Jonathan Wade Goldman

  • Krikor Bornazyan

  • Nicholas Dean Reese

  • Tina Wang

  • Paul Coluzzi

  • Blanca A. Ledezma

  • Melody A. Mendenhall

  • Benjamin Jones

  • John Madrigal

  • James M. Carroll

  • Jaklin Gukasyan

  • Tawny Williams

  • Lauren Sauer

  • Courtney L Wells

  • Ariana R Hardy

  • Paulina J Linares

  • Carlos R. Adame

  • Edward B. Garon

Medical Centers

  • UCLA, Los Angeles, CA

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

  • UCLA Care Center, Los Angeles, CA

  • UCLA David Geffen School of Medicine, Los Angeles, CA

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • UCLA Medical Center, Santa Monica, CA

  • UCLA David Geffen School of Medicine, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02879994

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved